Boston Scientific BSX
Boston Scientific is a multinational medical devices company that designs, manufactures, and markets a wide range of products for cardiovascular interventions, endoscopy, urology, and neuromodulation, selling directly to hospitals and health systems. Boston Scientific shows stable financial health (score 6.62) and a reasonable moat quality (score 6.62), but the valuation (score 6.65) reflects a P/E of 17.78 which, while not expensive, does not offset the competitive pressure from Cordis and the 52% drop in the stock price.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Boston Scientific is a multinational medical devices company that designs, manufactures, and markets a wide range of products for cardiovascular interventions, endoscopy, urology, and neuromodulation, selling directly to hospitals and health systems. Boston Scientific shows stable financial health (score 6.62) and a reasonable moat quality (score 6.62), but the valuation (score 6.65) reflects a P/E of 17.78 which, while not expensive, does not offset the competitive pressure from Cordis and the 52% drop in the stock price.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.6 |
| Quality / Moat | 6.6 |
| Valuation | 6.4 |
| Growth | 6.4 |
| Dividend | 1.5 |
| Momentum | 0.3 |
| Risk & Context | 7.7 |
OVERALL SCORE: 5.8/10
Context and risks
The medical device sector is under regulatory pressure in the US (Inflation Reduction Act) and BSX has exposure to product litigation (mesh). The FDA approval to competitor Cordis increases competitive pressure.
News considered in the analysis
- Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know — Movimiento de precio rutinario sin información fundamental nueva; ruido de mercado.
- How Far Can BSX Stock Swing After Losing More Than Half Its Value? — El artículo especula sobre la volatilidad futura tras la fuerte caída, pero no aporta un catalizador concreto; el impacto es incierto y ya está parcialmente descontado.
- Cordis wins FDA approval for sirolimus-eluting balloon — La aprobación de un competidor en el mercado de balones liberadores de fármaco podría presionar la cuota de mercado de BSX en el segmento de intervenciones coronarias.
- 2 Value Stocks with Exciting Potential and 1 We Avoid — Listículo genérico sin información específica sobre BSX; sin impacto.
- Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase? — El artículo destaca el potencial de los nuevos lanzamientos de productos para impulsar el crecimiento, un factor positivo moderado que el mercado ya anticipa en parte.
Verdict: Hold; the FDA approval for Cordis and regulatory pressure warrant caution, but the 15.1% earnings growth and a forward P/E of 12.87 offer some margin of safety.
Main risk: The FDA approval for Cordis for a sirolimus-eluting balloon could erode BSX's market share in the coronary interventions segment, a direct competitive risk.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →